Brainomix's AI Offensive: Decoding Lung Disease, Redefining Markets

OXFORD, England – August 25, 2026 – A press release dropped today that, on the surface, looks like standard MedTech fare: Oxford-based Brainomix will present five new studies at the prestigious European Respiratory Society (ERS) Congress in September. But read between the lines, and you're seeing the calculated next move from an AI powerhouse extending its reach. This isn't just about better science; it's about cornering a market by transforming how we see, measure, and manage a complex and devastating class of diseases.

Brainomix, a name synonymous with revolutionizing acute stroke care, is now making a formidable push into pulmonology. The five abstracts, all centered on its AI-powered platform for Interstitial Lung Disease (ILD), represent more than just clinical evidence. They are a declaration that the subjective, often-delayed art of diagnosing lung fibrosis is being replaced by the objective, data-driven science of AI. For investors, healthcare systems, and pharmaceutical giants, this is a signal of a major industrial transformation in chronic disease management.

An AI Lens on a Complex Disease

Interstitial Lung Disease isn't a single condition but a group of over 200 disorders characterized by inflammation and scarring (fibrosis) of the lungs, making breathing progressively difficult. Diagnosing the specific type of ILD and tracking its progression has long been a challenge, relying heavily on the trained eye of specialist radiologists interpreting CT scans—a process prone to variability and delays. For patients with aggressive forms like Idiopathic Pulmonary Fibrosis (IPF), diagnostic delays, which can stretch for years, are a death sentence.

Enter Brainomix 360 e-Lung. The FDA-cleared and CE-marked platform is an AI-driven software that automates the analysis of lung CT scans. It doesn't just look for patterns; it performs quantitative CT analysis, generating objective, repeatable metrics. The software identifies and measures radiographic features like ground-glass opacities and fibrotic scarring, producing scores like the "Weighted Reticulovascular Score" (WRVS). This transforms a subjective image into a hard data point that can be tracked over time.

"These five studies build on Brainomix's growing legacy of clinical evidence in quantitative imaging for fibrotic lung disease," said Prof Peter George, a Consultant Pulmonologist who also serves as Senior Medical Director at Brainomix. He emphasized the technology's potential to "deliver objective insights across the Interstitial Lung Disease (ILD) patient journey," from diagnosis and risk stratification to monitoring treatment response.

The Story Behind the Numbers: From Stroke to Lungs

To understand the significance of this move, you have to look at Brainomix's track record. Born from the University of Oxford in 2010, the company first established its dominance in the hyper-competitive stroke imaging market. Its flagship platform, Brainomix 360 Stroke, is used in over 300 hospitals across more than 20 countries and has been applied to over 1.5 million patient cases. A landmark 2025 study in The Lancet Digital Health confirmed its real-world impact, showing its use correlated with a 100% increase in thrombectomy rates—a critical, time-sensitive intervention.

This isn't a pivot; it's a strategic expansion. Brainomix is leveraging its core expertise in AI-powered image analysis and deploying it in a new, underserved vertical. The move is backed by serious capital, including an £18.8 million extended Series C funding round closed in February 2026, explicitly earmarked to fuel its U.S. expansion and platform development. By proving its model in the high-stakes world of acute stroke, Brainomix built the credibility and technological backbone to tackle the complexities of chronic lung disease.

The Barcelona Briefing: Clinical Muscle on Display

The upcoming ERS Congress in Barcelona is the perfect stage. As the premier global gathering for respiratory experts, it offers a platform to present compelling evidence to the very clinicians Brainomix needs to win over. The five studies are a tactical barrage aimed at demonstrating the platform's utility across the entire spectrum of ILD care.

The presentations will cover:
* Treatment Response: A post-hoc analysis of a Phase 2a trial for the drug taladegib, showing the e-Lung platform could detect increased lung volume and regression of ILD markers.
* Prognostic Power: A study linking telomere shortening—a genetic marker of aging—with quantitative CT measures of disease burden and mortality risk.
* Predicting Progression: A post-hoc analysis of the major INBUILD trial, demonstrating that early changes in AI-driven biomarkers are associated with future lung function decline.
* Risk Stratification: Research on identifying IPF patients who are also at risk of developing pulmonary hypertension, a serious complication.

This body of evidence goes far beyond academic interest. A recent U.S. multicenter study (REVISE PPF) showed that e-Lung could have accelerated the diagnosis of progressive pulmonary fibrosis by up to 21 months in over 60% of patients. In a field where time is tissue, that is a game-changing value proposition.

Redefining Patient Care and the Road Ahead

The implications of this technology extend beyond a single company's bottom line. By providing an objective, standardized tool, AI platforms like e-Lung can democratize expertise, enabling community hospitals to deliver a level of diagnostic precision previously confined to academic centers. This not only shortens the diagnostic journey for patients but also empowers pharmaceutical companies to run more efficient clinical trials by using quantitative imaging biomarkers as endpoints.

Of course, the road ahead is not without its challenges. The "black box" nature of some AI algorithms remains a concern for clinicians who demand interpretability. Issues of data governance, integration into existing hospital IT workflows, and the need for large-scale prospective validation are all hurdles that the industry, not just Brainomix, must overcome.

However, Brainomix is clearly playing the long game. By building a robust foundation of clinical evidence, securing regulatory approvals, and demonstrating a clear impact on patient outcomes, the company is not just selling software. It is building the infrastructure for a new paradigm in precision medicine, where treatment is guided not by subjective interpretation, but by the irrefutable story told by the numbers.